We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 23% above its sector, the market expects faster growth.
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save INDSWFTLAB.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
